Xtant Medical Focuses on Biologics After Successful $10.7 Million Asset Sale

Xtant Medical Strengthens Focus on Biologics Following Key Asset Sale

Xtant Medical Holdings, Inc., a renowned player in the medical technology sector, enhances its strategic focus following the receipt of $10.7 million from Companion Spine. This payment is part of the company’s divestiture of its Coflex® assets and Paradigm OUS business, transactions completed in December 2025. The latest payment not only raises the total proceeds from the sale to $21.4 million but also underscores Xtant's commitment to refocusing on its core expertise in higher-margin biologics. As a specialist in surgical solutions for spinal and orthopedic conditions, Xtant is now positioned to streamline operations and innovate further within its primary business lines.

The recent transaction brings significant financial relief to Xtant Medical. Of the $10.7 million received, $8.2 million alleviates an unsecured promissory note previously issued by Companion Spine, which includes accrued interest. The company is poised to benefit from the remaining $2.2 million which is allocated for adjustments relating to working capital and other sale-related financial matters. This strategic maneuver allows Xtant to not only reduce its long-term debt but also to bolster its cash liquidity, thereby enhancing its overall financial stability. Sean Browne, the President and CEO of Xtant, articulates a strong satisfaction with the completion of these divestitures, as they facilitate a more concentrated approach toward developing and advancing its biologic offerings.

Moreover, the sale of Coflex® assets positions Xtant Medical to concentrate on its mission of designing and commercializing a diverse portfolio of orthobiologics aimed at chronic and surgical wound care, alongside spinal implant systems. With a clear focus on increasing the efficiency of their operations, the company is dedicated to improving patient outcomes while honoring its commitment to ethical business practices. The transition of assets also aligns with Browne's remarks about the necessity of operating with integrity and a steadfast dedication to customer service, which is integral to the company’s long-term growth strategy.

In addition to the financial upswing, this strategic pivot allows Xtant Medical to innovate in the field of orthobiologics more effectively. The company can now channel its resources into developing new therapeutic options aimed at enhancing recovery for patients undergoing spinal and orthopedic surgeries. As Xtant continues to navigate its evolving landscape, its commitment to patient care and service remains paramount.

By directing its efforts towards biologics and optimizing its operational capabilities, Xtant Medical positions itself for future growth in a competitive market characterized by rapid technological advancements and changing healthcare dynamics.